1. Home
  2. AEMD vs PPBT Comparison

AEMD vs PPBT Comparison

Compare AEMD & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$2.46

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$1.68

Market Cap

2.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEMD
PPBT
Founded
1984
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
2.4M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
AEMD
PPBT
Price
$2.46
$1.68
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$15.00
$30.00
AVG Volume (30 Days)
115.6K
32.6K
Earning Date
02-12-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.41
52 Week High
$5.89
$5.18

Technical Indicators

Market Signals
Indicator
AEMD
PPBT
Relative Strength Index (RSI) 65.30 63.87
Support Level $2.00 $1.38
Resistance Level $3.11 $1.85
Average True Range (ATR) 0.22 0.12
MACD -0.08 0.04
Stochastic Oscillator 87.36 94.70

Price Performance

Historical Comparison
AEMD
PPBT

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.

Share on Social Networks: